Acurx Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Acurx Pharmaceuticals began enrolling patients on September 29, 2026, in its fully funded 20-patient Pathfinder trial in multiply recurrent C. difficile infection (CDI).
- For the three months ended September 30, 2026, research and development expenses were $1.1 million, compared with $0.4 million in the same period of 2025, while general and administrative expenses were $1.5 million, compared with $1.6 million.
- For the nine months ended September 30, 2026, research and development expenses were $2.5 million, compared with $1.6 million, and general and administrative expenses were $4.1 million, compared with $4.9 million.
- Net loss was $2.6 million, or $0.49 per diluted share, for the three months ended September 30, 2026, compared with $2 million, or $1.23 per diluted share, in the same period of 2025.
- Net loss was $6.5 million, or $1.59 per diluted share, for the nine months ended September 30, 2026, compared with $6.4 million, or $5.01 per diluted share, in the same period of 2025.
- Acurx ended the quarter with $9.7 million in cash, compared with $7.6 million as of December 31, 2025, and raised approximately $1.5 million of gross proceeds through its equity line of credit during the quarter.
- Acurx reported 5,879,237 shares outstanding as of September 30, 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Greetings. Welcome to the Acurx Pharmaceuticals Third Quarter 2026 Financial Results. At this time, all participants will be in listen-only mode. Question and answer session will follow the formal presentation. If anyone should require operator assistance during today's conference, please press star 0 on your telephone keypad. Please note that this conference is being recorded. At this time, I'll now turn the conference over to Rob Shawah, Chief Financial Officer.
Please go ahead. Thank you, Rob.
Good morning, and welcome to our call. This morning, we issued a press release providing financial results and company highlights for the third quarter 2026, which is available on our website at acurxpharma.com. Joining me today is David Luci, President and CEO of Acurx, who will start by providing a corporate update and outlook. Following that, I'll provide some highlights of the financials from the third quarter ended September 30th, and then turn the call back over to Dave for his closing remarks. As a reminder, during today's call, we'll be making certain forward-looking statements, which are based on current information, assumptions, estimates, and projections about future events that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in forward-looking statements.
Investors should consider these risks and other information described in our filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, which we filed today, Thursday, November 12th. You are cautioned not to place undue reliance on these forward-looking statements, and Acurx disclaims any obligation to update such statements at any time in the future. This conference call contains time-sensitive information that's accurate only as of the date of this live broadcast, today, November 12th, 2026. I'll now turn the call over to David Luci.
Dave? Thanks, Rob. Good morning, everyone, and thank you so much for joining us to review our financial results for the third quarter 2026, and also to hear some recent updates on our continuing progress.
Then we'd be pleased to take any questions. Our Executive Chairman, Bob DeLuccia, and our Senior Medical Advisor, Dr. Michael Silverman, have joined us today and will be available to answer questions about our ongoing clinical trial in patients with recurrent C. diff infection. First, I'd like to briefly summarize just a few of our key activities for the third quarter of 2026, or in some cases, shortly thereafter. First, in July 2026, the company's R&D team met with the FDA for the purpose of seeking their guidance on our plan to conduct a single phase III study in acute C.
difficile infection, or CDI, and its acceptability as a pivotal trial for filing a new drug application. We reported the outcome of this meeting in more detail in our August 3rd press release. Briefly, the FDA stated that it is open to further discussion on the totality of evidence from the ibezapolstat clinical development program at a pre-NDA meeting after we complete a single phase III trial, called ASPIRE, for the treatment of acute CDI and the reduction of recurrence, and the data from the PATHFINDER trial that is currently enrolling patients in recurrent CDI. Based on our discussions, FDA will focus on whether our clinical efficacy data from PATHFINDER and ASPIRE is robust enough to support an NDA submission. Second, on September 29th of this year, we began enrolling patients in the PATHFINDER 20-patient groundbreaking clinical trial in multiply recurrent CDI.
This trial was acknowledged by FDA as being significant, and along with robust results from our ASPIRE trial, may form the basis for a potential approval for the treatment of both acute CDI and prevention of recurrence. The PATHFINDER trial is fully funded, and if successful, will elevate the product profile of ibezapolstat. If the PATHFINDER trial is successful, we may have the flexibility to conduct a pivotal phase III trial, or PATHFINDER 2, in recurrent CDI under the FDA's LPAD pathway, instead of conducting the ASPIRE trial in acute CDI to gain an approval. A successful PATHFINDER trial may lead to an opportunity to gain approval with a smaller phase III program, and the ASPIRE trial in that scenario would become a post-approval supplemental NDA submission for the broader CDI population.
Thirdly, in August 2026, the company received FDA conditional acceptance and USPTO trademark allowance of its proprietary or brand name for ibezapolstat, which is CIFBEZY. These initial milestones will form the basis for the commercial identity of ibezapolstat as the company prepares to advance toward a phase III trial or trials and commercialization. Fourth, in September, the company announced its presentation of a scientific poster at the International C. difficile Symposium, demonstrating superior in vitro kill kinetics of ibezapolstat versus standards of care, vancomycin and fidaxomicin, against C. difficile, including vancomycin-resistant Enterococcus. These findings demonstrate that Enterococcus creates a protective shield that actively impairs C. difficile killing using standard of care antibiotics, but not with ibezapolstat. Ibezapolstat maintained superior bactericidal activity, including further decreasing C. difficile toxin B expression while simultaneously eradicating vancomycin-resistant bacterial growth.
Fifth, in July, we signed a continuation of our scientific partnership with Leiden University Medical Center in Holland to advance development of Acurx's DNA Pol III inhibitors. This new partnership builds on the previously reported successful results from the innovative research grants received in August 2021 and November 2025 from Health Holland to Leiden University and Acurx. This continuing partnership will enable further mechanistic research into DNA Pol III inhibition to accelerate the development of novel new antibiotics that are systemically active against a range of Gram-positive pathogens resistant to currently available antibiotics. This new research also aims to generate the first-ever 3D structure of Pol C from methicillin-resistant Staphylococcus aureus in complex with an Acurx inhibitor to advance discovery of new compounds to treat this high-priority clinical pathogen as designated by the CDC and the FDA.
Also in July, a presentation of scientific data by Dr. Kevin Garey and his laboratory team at University of Houston College of Pharmacy demonstrated that following treatment in his state-of-the-art laboratory model with ibezapolstat, the beneficial microorganisms in the gut have the opportunity to repopulate the microbiome in a beneficial way that prevents recurrence. In addition, ibezapolstat and fidaxomicin were superior in biofilm experimental models, with ibez significantly more effective at killing C. diff than either vancomycin or fidaxomicin. In October, we announced the publication in the ASM, American Society for Microbiology, Spectrum Journal, confirming data on our DNA Pol III inhibitor pipeline of antibiotics, demonstrating a potential microbiome-sparing class effect. This was the first-ever head-to-head comparison of gut microbiome changes associated and reduced MRSA bacterial burden while preserving microbiome metabolic function, in contrast to the marked disruption by linezolid.
Eighth, in October, Acurx presented at the Pipeline and Innovation Theater at IDWeek, the 2026 Scientific Conference of the Infectious Diseases Society of America, held in Washington, D.C., October 21 to 24. Our Executive Chairman, Bob DeLuccia, and Dr. Gino Girardi, Acurx Director of Clinical Research, presented an update on our progress and highlighted the open enrollment of our PATHFINDER trial at clinical research sites across the country. Bob and Gino also discussed our previously announced FDA guidance from our July 2026 FDA Type C Meeting to discuss ibezapolstat phase III clinical program, including the potential to submit an NDA based on a single phase III trial and a clinical trial design intended to support indications for both the acute treatment and the reduction of recurrence of CDI.
The predominant theme at the conference was a call to action to address antimicrobial resistance and the need for new antibiotics that respect both antimicrobial and microbiome stewardship. Acurx is at the forefront of pioneering microbiome stewardship by discovering and developing innovative narrow-spectrum antibiotics that cause minimal gut dysbiosis, a paradox with today's antibiotics. In August of this year, the company received approval from the Japan Patent Office and the Mexico Patent Office, respectively, for newly granted patents that protect Acurx's DNA Pol III inhibitors, including composition of matter, method of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent additions to the company's expanding series of granted patents in the U.S. and abroad.
To date, we've secured U.S. and international patents, including Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all of which protect key assets of the company's ibezapolstat and ACX-375C program targeting DNA Pol III. The ibezapolstat patents currently run through June 2042, subject to extensions that may be available. More importantly, the company has 10 years of regulatory exclusivity from the date of FDA approval based on its designation as a QIDP product and status as a new molecular entity. Additional country-level patents remain under review. We continue to identify and pursue funding opportunities for our phase III pivotal trial program for ibez for the treatment of both acute CDI and the reduction of recurrence. We've got several initiatives underway to this end and will report our progress in future updates.
As we've continually reported, ibezapolstat clinical and non-clinical results continue to outperform in a serious and life-threatening infectious disease called C. difficile bacteria that the CDC categorizes as a serious threat and calls for new classes of antibiotics for initial treatment that have a low incidence of recurrence. Furthermore, IBZ has FDA QIDP and fast-track designations for the treatment of CDI, as well as SME status in the EU. All Acurx compounds in preclinical development are eligible for QIDP and fast-track designations and target Gram-positive infections classified as serious threat priorities by the CDC and the FDA. In closing today, as you may expect, we're very excited to report the start of enrollment for our groundbreaking Phase III trial and the continued successful development of IBZ across the board.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
